CCRM Ireland Would Be Established to Hasten Translation of Advanced Therapies Into...
Rinn Advanced Therapies, Ireland’s national research center for personalized immune cell therapies, signed a Memorandum of Understanding (MOU) with CCRM, which focuses on cell and gene therapy development and commercialization. The agreement outlines a strategic collaboration to explore establishing a CCRM-affiliated advanced therapies hub in Ireland.
The proposed initiative, referred to as CCRM Ireland, is designed to position Ireland as a key node within CCRM’s global network of advanced therapies hubs and further strengthen Ireland’s expertise in next-generation biomedicine. CCRM’s global network comprises CCRM in Canada, CCRM Australia, and CCRM Nordic in Sweden.
“The idea of collaborating with CCRM to establish CCRM Ireland is very attractive because of our shared commitment to improving patient outcomes,” said Sakis Mantalaris, PhD, director of Rinn Advanced Therapies. “By combining Rinn Advanced Therapies’ focus on novel personalized immune cell therapeutics with CCRM’s global platform, CCRM Ireland can accelerate the translation of cutting-edge science into accessible, high-quality treatments.”
Through this collaboration, Rinn Advanced Therapies will lead the evaluation of how Ireland’s integrated ecosystem—spanning academia, health care, biomanufacturing and research—can be aligned with CCRM’s model for accelerating the development of advanced therapies. The partnership will explore how to advance the design and clinical translation and delivery of personalized immune cell therapies, while also leveraging Ireland’s biopharmaceutical manufacturing skills.
CCRM Ireland would potentially support investment, venture creation and commercialization pathways, following CCRM Canada’s proven model.
“As cell and gene therapies move from scientific promise to clinical reality, no single organization, region or country can build this industry alone,” says Michael May, president and CEO, CCRM. “CCRM’s global hubs are designed to connect world-class research, manufacturing expertise, capital and talent into a coordinated network that accelerates the development and commercialization of advanced therapies.
By creating hubs around the world, and in the spirit of the Prime Minister of Canada’s call for middle-power countries to work together, with CCRM Ireland, we can help innovators overcome barriers to scale, strengthen local ecosystems and, most importantly, bring life-changing treatments to patients faster.”
Rinn Advanced Therapies brings together a network that includes universities, hospitals, and national organizations with a shared mission to develop and deliver personalized immune cell therapies that are more effective, accessible and affordable for patients.
CCRM will contribute its expertise in establishing and operating advanced therapies hubs, drawing on its experience in Canada and its growing international network. This includes proven frameworks in governance, GMP manufacturing, quality systems and commercialization.
NewsCell immunotherapyDrug research and developmentGene therapy (Therapeutics)Good manufacturing practicePrevious article
Tecan Integrates Agentic AI Into Its Introspect Lab Analytics PlatformNext article
Shilpa Commissions Integrated ADC Drug Substance GMP Manufacturing FacilityAlso of Interest
CAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research Collaboration10 CDMO Up & Comers 2026Purifying Complex Therapeutics Requires Fresh ApproachesGene Therapy Extends Lifespan and Reduces Symptoms in Sandhoff Disease Cat ModelDesign for Commercial Scale from Day OneManaging Misbehaving mAbs with Advanced Purification StrategiesRelated Media
In Conversation with Visionary Geneticist George ChurchBoston's Bioprocessing Buzz:GENReports Live from BPI 2025Smart Vector Design for Improved Cell and Gene TherapiesBiotech and Beignets: The News from Day One of ASGCTPrecision Base Editing Meets Single-Cell Multiomics to Advance Cell and Gene TherapiesBye, Bye, Baltimore:GEN’s Takeaways from ASGCTTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter